Alport syndrome
MONDO:0018965A rare renal disease characterized by glomerular nephropathy with hematuria progressing to end-stage renal disease (ESRD), frequently associated with sensorineural deafness, and occasionally with ocular anomalies.
Also known as: hereditary nephritis, Alport deafness-nephropathy, Alport syndrome, Alport's syndrome
20 clinical trials for this condition and its sub-types, 17 tagged with Alport syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Alport syndrome
-
X-linked Alport syndrome 3 trials
-
Autosomal recessive Alport syndrome 2 trials
-
Autosomal dominant Alport syndrome 0 trials
-
Digenic Alport syndrome 0 trials
-
New kidney drug shows promise in reducing protein leakage
Disease control Recruiting nowThis study tests an experimental tablet, BI 764198, in adults and some teens with four types of kidney disease that cause protein in the urine. Participants take the drug or a placebo daily for 20 weeks while continuing their usual care. The main goal is to see if the drug lowers…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug aims to slow kidney damage in rare alport syndrome
Disease control Recruiting nowThis study tests a drug called exaluren in 24 people aged 12 and older with Alport syndrome caused by specific genetic errors. The drug is given as a daily shot for 32 weeks. Half the group starts exaluren right away, while the other half gets a placebo first and then switches to…
Phase 2 • Sponsor: Eloxx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New hope for kids with rare kidney diseases: drug trial aims to cut protein leak
Disease control Recruiting nowThis study tests an oral drug called sparsentan in 67 children with certain kidney diseases that cause protein to leak into urine. The goal is to see if the drug safely reduces protein levels over 108 weeks. Participants must have a certain level of kidney function to join.
Phase 2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Study links gum health to rare kidney diseases
Knowledge-focused Recruiting nowThis study looks at gum disease in people with rare kidney disorders like Alport syndrome, Fabry disease, and tuberous sclerosis, as well as lupus. Researchers will compare 100 participants to those with chronic kidney disease and healthy controls. They aim to understand how comm…
Sponsor: Stefan Lujinschi • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Personalized trial matching could revolutionize kidney disease treatment
Knowledge-focused Recruiting nowThis study helps people with certain kidney diseases (like nephrotic syndrome and FSGS) find clinical trials that match their specific disease profile. Researchers analyze participants' molecular data to recommend targeted therapies in ongoing trials. The goal is to improve treat…
Sponsor: University of Michigan • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Alport patients needed: join a registry to speed up research
Knowledge-focused Recruiting nowThis registry is for people in the US with Alport syndrome. It collects health information over time through a secure online portal. The goal is to gather real-world data to help researchers understand the disease better and design future clinical trials. No treatments or medicat…
Sponsor: Alport Syndrome Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Massive european study aims to unlock secrets of rare kidney disease
Knowledge-focused Recruiting nowThis study follows 700 people with Alport syndrome, a rare inherited disease that can lead to kidney failure, hearing loss, and eye problems. Researchers will collect health data and samples over time to map how the disease progresses and to find early markers of kidney decline. …
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:47 UTC